Title: Efficacy and safety of Axicabtagene ciloleucel (Axi‐cel) for the treatment of relapse/refractory non‐Hodgkin lymphoma: First real‐world data in Chinese population.
Authors: Zhao, W. L.; Li, Y. H.; Zou, D. H.; Zhu, X. J.; Ji, D. M.; Qian, W. B.; Lu, Y.; Ji, C. Y.; Zhou, K. S.; Jing, H. M.; Yang, H.; Li, L. F.; Li, F.; Xu, K. L.; Niu, T.; Wu, D. P.; Hu, Y.
Abstract: B Background: b Axi-cel was approved by NMPA to treat R/R LBCL adult patients who had received 2 or more prior treatments in 2021 June. Eighty-one patients experienced cytokine release syndrome (CRS) of any grade, and 16 (15.2%) patients occurred grade 3 or higher. The median prior lines of therapy was 2, including 36 (35.6%) patients got >=3 previous treatments and 10 patients had history of ASCT.
Subjects: NON-Hodgkin's lymphoma; CHINESE people; CYTOKINE release syndrome
Publication: Hematological Oncology, 2023, Vol 41, p457
ISSN: 0278-0232
Publication type: Academic Journal
DOI: 10.1002/hon.3164_337

Efficacy and safety of Axicabtagene ciloleucel (Axi‐cel) for the treatment of relapse/refractory non‐Hodgkin lymphoma: First real‐world data in Chinese population.

Zhao, W. L.; Li, Y. H.; Zou, D. H.; Zhu, X. J.; Ji, D. M.; Qian, W. B.; Lu, Y.; Ji, C. Y.; Zhou, K. S.; Jing, H. M.; Yang, H.; Li, L. F.; Li, F.; Xu, K. L.; Niu, T.; Wu, D. P.; Hu, Y.